Eli Lilly and Co
Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. Mike Blake | Reuters Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes drug, Mounjaro. […]
Read More
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. Victoria Klesty | Reuters Novo Nordisk‘s parent company on Monday said it will acquire drug manufacturer Catalent in a $16.5 billion deal that could help boost the supply of the highly popular weight loss injection […]
Read More
Wall Avenue heads into the 7 days in advance worrying the rally to document highs is managing out of steam
Wall Street continues to climb a wall of fret even as investors deliberate how significantly more time equities can preserve their report operate. The stock rally continued on Friday , with the main averages each individual advancing additional than 1% for the week, buoyed by robust final results from Meta and Amazon, as effectively as […]
Read More
Here are Jim Cramer’s rapid-fire takeaways on 6 stocks in the news Friday
Clorox – The consumer products giant saw a huge earnings beat. It’s also rebounding from last year’s cyberattack. “Things are back online, and there’s tremendous demand for their product,” Jim said Friday’s Morning Meeting rapid fire. Tesla – The EV leader issued a recall for 2.2 million cars over a warning light issue. Remember, our […]
Read More
January was great for stocks — here are our top 5 performers for the month
Benchmark gauges notched all-time highs as stocks charged through a busy earnings season. Source
Read More
Want to cash in on the fat-reduction drug increase? Morgan Stanley names 4 global shares
Drug makers these kinds of as Eli Lilly and Novo Nordisk have been very hot favorites among the traders in the previous 12 months, specified the favourable reception to their pounds-decline medications. “The uptake of GLP-1 (glucagon-like-pepitide-1) course AOMs (anti-weight problems drugs) has been unexpectedly robust, specially in the U.S. the place the medicines are […]
Read More
Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters Norway’s giant wealth fund, the world’s largest, touted the possibility that Danish drugmaker Novo Nordisk and U.S. rival Eli Lilly […]
Read More
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People’s Action, protesting pharmaceutical companies’ lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021. Saul Loeb | AFP | Getty Images The CEOs of Merck and […]
Read More
Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
Hopes are sky-high for Eli Lilly’s recently launched weight loss drug Zepbound. Investors will be tuning into the company’s fourth quarter earnings call on Feb. 6, eager to hear more about how that rollout is going. One key statistic will be the number of commercial health insurers providing coverage of the drug, which was approved […]
Read More
Missed the Novo and Lilly rally? These 4 under-the-radar anti-obesity drug stocks could soar, Berenberg says – giving one 44% upside
The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. The Germany-headquartered investment bank expects a combination of new clinical data, and the expiry of Novo ‘s patent for the active ingredient in first-generation GLP-1 drugs, […]
Read More